How do I buy Capricor Therapeutics, Inc. Common Stock (CAPR) stock?

Buying Capricor Therapeutics, Inc. Common Stock (CAPR) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "CAPR", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy CAPR by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if CAPR is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Capricor Therapeutics, Inc. Common Stock (CAPR) Stock

Q: What is the minimum investment for CAPR on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Capricor Therapeutics, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NASDAQ · CAPR

Trade CAPR

Key stats

Market cap: $652.35M
Price / Earnings ratio: -4.0x
EPS (TTM): -$2.45
Volume: Loading
52-week high: $40.37
52-week low: $2.96

Source: third-party data provider, as of November 13, 2026

Compare with CAPR

Technical indicators

RSI 14: 69.36
MACD 12/26/9: 0.55
EMA 9 of MACD: 0.05
MACD histogram: 0.50
SMA 50: $8.09; Price above SMA 50
EMA 50: $8.64; Price above EMA 50
SMA 200: $20.16; Price below SMA 200
EMA 200: $17.30; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Buy

Based on 4 analyst ratings

Strong Sell0

Sell0

Hold0

Buy4

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2021

2022

2023

2024

2025

30M20M10M0

Debt & Balance Sheet

Total assets

Total liabilities

2021

2022

2023

2024

2025

427M282M141M0

Revenue to Profit

2025

$0.0

Revenue

$0.0

Cost of revenue

$0.0

Gross profit

$0.0

Operating expenses

$-105.0M

Net income

Earnings

No data available

Source: third-party data provider

About Capricor Therapeutics, Inc. Common Stock

No description available.

SectorHealthcare

IndustryBiotechnology

Employees231

CEODr. Linda Marbán Ph.D.

IPO DateFeb 13, 2007

HeadquartersSan Diego, CA

Key Executives

Name	Title	Year Born
Dr. Linda Marbán Ph.D.	Co-Founder, President, CEO & Director	1963
Dr. Frank Isaac Litvack FACC, M.D.	Executive Chairman of the Board	1956
Mr. Anthony J. Bergmann M.B.A.	CFO & Corporate Treasurer	1986
Ms. Karen G. Krasney Esq., J.D.	Executive VP, General Counsel & Secretary	1953
Dr. Kristi A. H. Elliott Ph.D.	Chief Operating & Science Officer	—
Mr. Minghao Sun Ph.D.	Senior Vice President of Quality Control, Research & Product Development	—
Mr. Mark Awadalla	Chief Development Officer	—
Dr. Micheal Binks M.D.	Chief Medical Officer	—
Mr. Michael Maurer	Chief Commercial Officer	—
Nathaniel Hogan Ph.D.	Director of Biostatistics of Capricor Therapeutics	—

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											-1.5	-8.7
2022	+12.3	+10.4	-20.4	-11.7	+4.3	-1.7	+25.3	+32.6	+1.4	-8.9	-17.8	-10.9
2023	+9.6	+7.6	-16.1	-7.6	+15.9	+5.1	-6.4	+41.2	-48.3	-5.1	+6.1	+65.2
2024	-21.1	+3.2	+48.6	-25.8	+6.6	-15.4	-16.1	+16.9	+248.1	+33.9	-2.3	-29.7
2025	+0.5	+1.3	-30.6	+34.0	-22.4	-2.7	-15.7	-20.5	+13.9	-16.8	-11.9	+334.0
2026	-22.7	+21.0	+13.2	+11.5	-3.1	-15.6	-83.3	+136.0	-5.4	-28.6	+55.0

Stocks in the same sector

Vertex Pharmaceuticals

ABEO

Abeona Therapeutics Inc.

FAQ

Buying Capricor Therapeutics, Inc. Common Stock (CAPR) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and verify your identity.
Make a deposit.
Search for the code "CAPR", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy CAPR by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full share. With fractional shares, you can start investing in Capricor Therapeutics, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, Capricor Therapeutics, Inc. Common Stock (CAPR) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track CAPR's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too.

The market is closed on US public holidays. The Gotrade app shows whether the market is open.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trade Faster. Easier. Smarter.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Capricor Therapeutics, Inc. Common Stock (CAPR) Stock

Key stats

Compare with CAPR

Recent news

CAPR vs IBRX vs SLS vs IOVA: Whose Insiders Cashed Out The Most — And Who Bought Before A 5X Surge?

CAPR vs IBRX vs SLS vs IOVA: Whose Insiders Cashed Out The Most — And Who Bought Before A 5X Surge?

Nasdaq 100 Futures Drop As Reports Relating To Jensen Huang’s Ousting Outweigh CoreWeave’s Strong Outlook — NVDA, TSLA, SNDK, CAPR, CRWV In Focus

Nasdaq 100 Futures Drop As Reports Relating To Jensen Huang’s Ousting Outweigh CoreWeave’s Strong Outlook — NVDA, TSLA, SNDK, CAPR, CRWV In Focus

CAPR Stock Rallies: Investors Scrutinize Labeling Hints Before FDA Decision On Cell Therapy This Month

CAPR Stock Rallies: Investors Scrutinize Labeling Hints Before FDA Decision On Cell Therapy This Month

CAPR Stock Rallies After-Hours As Capricor Reaffirms Deramiocel Confidence Ahead Of Nov. 22 Decision; Says Application In Final Review

CAPR Stock Rallies After-Hours As Capricor Reaffirms Deramiocel Confidence Ahead Of Nov. 22 Decision; Says Application In Final Review

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

CAPR vs IBRX vs SLS vs IOVA: Whose Insiders Cashed Out The Most — And Who Bought Before A 5X Surge?

CAPR vs IBRX vs SLS vs IOVA: Whose Insiders Cashed Out The Most — And Who Bought Before A 5X Surge?

Nasdaq 100 Futures Drop As Reports Relating To Jensen Huang’s Ousting Outweigh CoreWeave’s Strong Outlook — NVDA, TSLA, SNDK, CAPR, CRWV In Focus

Nasdaq 100 Futures Drop As Reports Relating To Jensen Huang’s Ousting Outweigh CoreWeave’s Strong Outlook — NVDA, TSLA, SNDK, CAPR, CRWV In Focus

CAPR Stock Rallies: Investors Scrutinize Labeling Hints Before FDA Decision On Cell Therapy This Month

CAPR Stock Rallies: Investors Scrutinize Labeling Hints Before FDA Decision On Cell Therapy This Month

CAPR Stock Rallies After-Hours As Capricor Reaffirms Deramiocel Confidence Ahead Of Nov. 22 Decision; Says Application In Final Review

CAPR Stock Rallies After-Hours As Capricor Reaffirms Deramiocel Confidence Ahead Of Nov. 22 Decision; Says Application In Final Review

CAPR Stock Rises After Deramiocel Cardiac Data Wins American Heart Association Award Ahead Of FDA Decision

CAPR Stock Rises After Deramiocel Cardiac Data Wins American Heart Association Award Ahead Of FDA Decision

CAPR Stock Rises As Clinical Trial Investigators Write To FDA Urging Approval For Deramiocel

CAPR Stock Rises As Clinical Trial Investigators Write To FDA Urging Approval For Deramiocel

CAPR Stock Rallies Into FDA Decision Month: Retail Spots Approval ‘Tea Leaves’ In Capricor’s Launch Team Hiring

CAPR Stock Rallies Into FDA Decision Month: Retail Spots Approval ‘Tea Leaves’ In Capricor’s Launch Team Hiring

CAPR Stock on Track For Worst Month Since July AdCom Vote On Deramiocel As November FDA Decision Nears

CAPR Stock on Track For Worst Month Since July AdCom Vote On Deramiocel As November FDA Decision Nears

CAPR Stock Rises Nearly 5% As Capricor Presents Heart Data For Deramiocel Ahead Of November FDA Decision

CAPR Stock Rises Nearly 5% As Capricor Presents Heart Data For Deramiocel Ahead Of November FDA Decision

Capricor’s DMD Therapy Shows 76% Slower Upper-Limb Decline — This Analyst Expects A Complete Response Letter In November

Capricor’s DMD Therapy Shows 76% Slower Upper-Limb Decline — This Analyst Expects A Complete Response Letter In November

About Capricor Therapeutics, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade